Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Alder Biopharma (ALDR)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 859,142
  • Shares Outstanding, K 68,240
  • Annual Sales, $ 1,620 K
  • Annual Income, $ -288,880 K
  • 36-Month Beta 2.59
  • Price/Sales 540.75
  • Price/Cash Flow N/A
  • Price/Book 3.63

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate -1.13
  • Number of Estimates 5
  • High Estimate -0.99
  • Low Estimate -1.36
  • Prior Year -0.92
  • Growth Rate Est. (year over year) -22.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
12.17 +3.45%
on 10/12/18
17.20 -26.80%
on 09/25/18
-3.36 (-21.07%)
since 09/19/18
3-Month
12.17 +3.45%
on 10/12/18
20.87 -39.67%
on 08/08/18
-5.71 (-31.20%)
since 07/19/18
52-Week
9.55 +31.83%
on 11/14/17
20.87 -39.67%
on 08/08/18
+1.09 (+9.48%)
since 10/19/17

Most Recent Stories

More News
Alder Biopharmac Shares Down 22.1% Since SmarTrend's Sell Call (ALDR)

SmarTrend identified a Downtrend for Alder Biopharmac (NASDAQ:ALDR) on September 18th, 2018 at $16.73. In approximately 3 weeks, Alder Biopharmac has returned 22.09% as of today's recent price of $13.03....

ALDR : 12.59 (-1.87%)
The Zacks Analyst Blog Highlights: Alder, Xenon, Spero and Trevena

The Zacks Analyst Blog Highlights: Alder, Xenon, Spero and Trevena

TRVN : 0.82 (-4.65%)
ALDR : 12.59 (-1.87%)
SPRO : 8.52 (-0.18%)
XENE : 10.51 (-2.23%)
4 Healthcare Stocks Thriving on Venture Capital Funding

A steady influx of foreign as well as domestic investments in U.S. healthcare has gone a long way in boosting gains for the space.

BABA : 142.93 (+0.64%)
TRVN : 0.82 (-4.65%)
ALDR : 12.59 (-1.87%)
SPRO : 8.52 (-0.18%)
XENE : 10.51 (-2.23%)
Alder BioPharmaceuticals(R) Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today reported that the Compensation Committee...

ALDR : 12.59 (-1.87%)
Alder BioPharmaceuticals Enters Oversold Territory

Alder BioPharmaceuticals has been on a bit of a cold streak lately.

ALDR : 12.59 (-1.87%)
Alder BioPharmaceuticals(R) Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Alder BioPharmaceuticals, Inc. (Nasdaq: ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, today reported that the Compensation Committee...

ALDR : 12.59 (-1.87%)
Is Alder BioPharmaceuticals (ALDR) Outperforming Other Medical Stocks This Year?

Is (ALDR) Outperforming Other Medical Stocks This Year?

ALDR : 12.59 (-1.87%)
Alder BioPharmaceuticals Sees Hammer Chart Pattern: Time to Buy?

Alder BioPharmaceuticals has been struggling lately, but the selling pressure may be coming to an end soon.

ALDR : 12.59 (-1.87%)
Pivotal bioVenture Partners Appoints Accomplished Investor, Heather Preston, M.D., as Managing Partner

Pivotal bioVenture Partners, today announced the appointment of the accomplished biotechnology venture capital executive, Heather Preston, M.D., as a Managing Partner. Preston joins Managing Partners Rob...

ALDR : 12.59 (-1.87%)
Alder BioPharmaceuticals(R) Reports Second Quarter 2018 Financial and Operating Results

- Presented new eptinezumab Phase 3 clinical trial data in episodic and chronic migraine demonstrating robust efficacy that is sustained and further improved after repeat quarterly treatments -

ALDR : 12.59 (-1.87%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 80% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Trade ALDR with:

Business Summary

Alder Biopharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and seeks to commercialize therapeutic antibodies. It is developing monoclonal antibodies comprising ALD403, for the prevention of migraine; and Clazakizumab, in the treatment of rheumatoid arthritis and...

See More

Key Turning Points

2nd Resistance Point 13.49
1st Resistance Point 13.04
Last Price 12.59
1st Support Level 12.27
2nd Support Level 11.95

See More

52-Week High 20.87
Fibonacci 61.8% 16.55
Fibonacci 50% 15.21
Fibonacci 38.2% 13.87
Last Price 12.59
52-Week Low 9.55

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar